Tongrentang's response was named because of the disunity of Chinese and British standards

Tongrentang is really a "bad time", and this time it is again in the "toxic door" controversy The medicines and Health Products Administration issued a Chinese medicine warning on its website on Monday that some Chinese medicines contain large quantities of harmful toxins, including lead, mercury and arsenic Tongrentang is the manufacturer of one of its products To this end, Tongrentang staff said: the "named" Niuhuang Jiedu Tablets are produced according to the national regulations and meet the national safety standards The key problem is that the drug standards of the two countries are different Tongrentang (600085), fearing the negative news, closed at 22.98 yuan on the 21st, with its share price slightly up 0.13% A number of listed companies have been "listed" it is understood that the products warned this time include Niuhuang Jiedu tablet of Beijing Tongrentang, Baifeng pill of baolingtang and Fabao of henglongchang None of these products are authorized to enter the UK market, but investigators have found the drugs in the market Baifeng pills were previously recalled in Hong Kong because they contain twice the normal amount of lead But the mercury content in the hair treasure is 11 times of the standard In addition, they found that Niuhuang Jiedu Tablets produced by Beijing Tongrentang contain a large amount of arsenic In response, a staff member of Beijing Tongrentang said in an interview: this news is one-sided The company's Niuhuang antidote tablets are produced in accordance with national regulations and meet national safety standards, mainly because the drug standards of the two countries are different Reporters learned that Tongrentang has many brothers and sisters in the matter of falling into the "toxic door" Yunnan Baiyao, Hansen, Yingkang, etc have been listed successively The reporter learned from the official website of the State Administration of traditional Chinese medicine that the Ministry of Commerce and the State Administration of traditional Chinese medicine have recently officially launched the construction of key projects, key enterprises (Institutions) and key regions of traditional Chinese medicine service trade The two departments encouraged the "going out" of traditional Chinese medicine, which aims to explore the development mode of service trade of traditional Chinese medicine, establish service standards of traditional Chinese medicine and cultivate international famous service brands through three years' efforts It is understood that since the publication of the opinions of the Ministry of Commerce and other 14 departments on promoting the development of TCM service trade for more than one year, TCM service trade has increased significantly compared with the previous one, with both the export volume and the number of countries exporting both increasing "However, from the perspective of Tongrentang incident, we can see that in fact, the internationalization of traditional Chinese medicine has always been a stumbling block, and the recognition still needs to be greatly improved The key is that traditional Chinese medicine products should work harder in toxicity testing, drug composition analysis and adverse reactions, and do not avoid ambiguity, otherwise it may attract endless doubts and warnings." One industry observer said There is still an opportunity for Chinese medicine stocks to take a calm view of the black swan incident in the medium and long term Judging from yesterday's capital market reaction, it seems that they have completely ignored the British roll call "It is true that Chinese medicine plate is easy to produce black swans, but it is important We will analyze how serious the situation is, whether there is a conflict of ideas or whether there is a quality problem in the product." An industry observer told our reporter that when the news of "poison" of traditional Chinese medicine came out, there would be such phenomena as the decline of individual stocks involved and the sharp fall of plates But after a long test, the market has become more calm and objective than before "In the medium and long term, the traditional Chinese medicine sector is still very promising On the one hand, more and more traditional Chinese medicine has been included in the list of essential drugs, many of which are still exclusive varieties with bargaining power; on the other hand, the industry is being cleaned up and rectified at the national level, and its quality may rise to a higher level; on the other hand, the new medical reform encourages grass-roots medical institutions to develop traditional Chinese medicine, This will help a lot of common Chinese medicine to achieve large-scale growth " He said But he also reminded investors that in recent years, the prices of many pharmaceutical stocks have been rising and their valuations are on the high side, which needs to be corrected At the same time, pharmaceutical companies with long product lines and fast acquisition pace are more likely to be on the "black list" of quality "There have been large pharmaceutical companies buying small pharmaceutical companies before, but the quality control can't be extended so long, leading to the completion of the front foot purchase, the back foot accident, and the stock price has been dragged down in a row." He said.